Association of visfatin with chronic kidney disease in a cohort of patients with and without diabetes

To evaluate association of serum visfatin with CKD secondary to diabetic nephropathy and to compare it with patients of CKD secondary to other risk factors. Seventy eight individuals including 28 healthy controls and 50 patients of CKD were included in this study. Patients with CKD were further grou...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the Pakistan Medical Association 2010-11, Vol.60 (11), p.922-926
Main Authors: MAHMOOD, Nosheen, ABDUL MANAN JUNEJO, JAMAL, Qamar, AWAN, Rashid
Format: Article
Language:English
Subjects:
Adult
Biological and medical sciences
Biomarkers - blood
Body Mass Index
Case-Control Studies
Chronic Disease
Cohort Studies
Cytokines - blood
Diabetes Mellitus, Type 2 - blood
Diabetes Mellitus, Type 2 - physiopathology
Diabetes. Impaired glucose tolerance
Diabetic Nephropathies - complications
Endocrine pancreas. Apud cells (diseases)
Endocrinopathies
Etiopathogenesis. Screening. Investigations. Target tissue resistance
Female
General aspects
Humans
Kidney Failure, Chronic - blood
Kidney Failure, Chronic - physiopathology
Kidneys
Male
Medical sciences
Middle Aged
Nephrology. Urinary tract diseases
Nicotinamide Phosphoribosyltransferase - blood
Pakistan
Urinary system involvement in other diseases. Miscellaneous
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To evaluate association of serum visfatin with CKD secondary to diabetic nephropathy and to compare it with patients of CKD secondary to other risk factors. Seventy eight individuals including 28 healthy controls and 50 patients of CKD were included in this study. Patients with CKD were further grouped based on etiology of CKD into diabetics and non-diabetics. Patients with type 1 diabetes mellitus, urinary tract infection, urolithiasis, liver cirrhosis, stroke, ischaemic heart disease, and rheumatoid arthritis were excluded. Measurement of Serum visfatin was done through EIA Kit (Phoenix pharmaceuticals Burlingame CA). Visfatin concentration was significantly high in patients with CKD compared to controls (8.7 +/- 4.7 vs. 5.2 +/- 3.3 p = 0.001). No significant difference in Visfatin concentrations between patients of CKD with and without diabetes was detected (9.2 +/- 5.5 vs. 8.3 +/- 3.2 p = 0.694). A significant negative correlation of visfatin with estimated GFR (r2= -0.383, p = 0.01) and a positive correlation with degree of proteinuria (p = 0.01) was observed. The present study confirms the association of visfatin with CKD, however further studies at molecular level to check its expression within renal tissue may clarify its definitive role in CKD
ISSN:0030-9982